Allogeneic Bone Marrow Transplantation in Multiple Myeloma

摘要: Abstract Background and Methods. In contrast to autologous bone marrow transplants for hematologic cancers, allogeneic contain no tumor cells that might cause a relapse. We report the results of such transplantation using HLA-compatible sibling donors in 90 patients with multiple myeloma performed 26 European centers between 1983 1989. Results. At time most recent follow-up, 79 months after start study, 47 were alive 43 dead. The rate complete remission was percent all 58 who had engraftment. actuarial survival at 76 40 percent. median duration relapse-free among 48 months. stage disease diagnosis number treatment regimens tried before predictive likelihood remi...